- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07951242
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of a Children's Fiber Blend on Digestive Health and Gut Microbiome Composition in Children
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LOAM Kids Gut Starter Fiber Formula on Digestive Health and Gut Microbiome Composition in Children
This study evaluates the impact of a fiber blend supplement on gastrointestinal symptoms and the gut microbiome in children aged 3-6 with a history or irregular stooling.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Bryce Jarman
- Número de telefone: 323-325-1327
- E-mail: bryce@loamscience.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female child, aged 3-6 years (inclusive) at the time of enrollment.
- Caregiver reports the child consumes few vegetables, whole fruit, whole grains, or legumes per week (fewer than two per day on average), consistent with this study's operational definition of low dietary fiber intake.
- Caregiver reports infrequent or difficult bowel movements (constipation) in the child over the past four weeks
- Caregiver reports the child has experienced excess gas, or bloating, over the past four weeks
- Caregiver is willing and able to administer the study product to the child once daily with a meal for 4 weeks, complete digital questionnaires at Baseline, Weeks 1, 2, 3, and End of Study on behalf of the enrolled child, and to facilitate at-home microbiome stool sample collection at Baseline and End of Study and return samples per provided instructions.
- Child is generally healthy, without any acute or chronic condition that would preclude safe participation as determined by caregiver report.
- Caregiver is willing to maintain the child's current diet, sleep patterns, and activity levels throughout the study duration, and to avoid introducing new fiber supplements or probiotic/prebiotic products during the study period.
- Caregiver and child reside in the United States.
- Caregiver is willing and able to provide informed consent; child assent will be obtained where age-appropriate and consistent with IRB requirements.
Exclusion Criteria:
- Known milk allergy, dairy allergy, lactose intolerance, or any known sensitivity to milk-derived products. (The study product's active formulation contains a milk allergen.)
- Child is currently breastfeeding.
- Known allergy or sensitivity to any component of the study product.
- Currently receiving anticoagulant or antiplatelet medications (e.g., warfarin), due to potential interaction with Vitamin K2 contained in the study product.
- Diagnosis of, or current treatment for, any gastrointestinal disease or disorder, including but not limited to: inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, or diagnosed functional gastrointestinal disorders requiring medical management.
- Use of any prescription or over-the-counter laxative, stool softener, antidiarrheal medication, or fiber supplement on a regular basis (≥3 times per week) in the 4 weeks prior to enrollment, or intent to use during the study.
- Use of oral antibiotics or antifungals within 4 weeks prior to enrollment, or anticipated use during the study period.
- Use of any probiotic or prebiotic supplement (other than those naturally occurring in diet) in the 4 weeks prior to enrollment, or intent to use during the study.
- Significant acute illness, including fever, acute gastrointestinal infection, or other acute medical condition at the time of enrollment, or any chronic medical condition, developmental condition, or disability that, in the caregiver's judgment or per clinical guidance, would prevent the child from safely adhering to the study protocol.
- Any planned surgical procedure during the 4-week study period.
- Participation in another research study currently or within the past 30 days, or planned participation in any other research study during this study's duration.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
Color and taste matched placebo. |
|
Experimental: Fiber Blend
|
This fiber blend contains a blend of Bifidogenic fibers and HMOs |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stool Frequency
Prazo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported number of bowel movements per week |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Stool Consistency
Prazo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported stool consistency using the pediatric-adapted Bristol Stool Scale (one-seven, with one indicating hard lumpy stools and seven indicating soft liquid stools) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Digestive Comfort
Prazo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Digestive comfort assessed using a visual analog scale (one-five, with one being very bad and five being very good) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Microbiome Composition
Prazo: Baseline, End of Study (Week 4)
|
Determined using shotgun metagenomic sequencing |
Baseline, End of Study (Week 4)
|
|
Gas and Bloating
Prazo: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Gas and bloating assessed using a visual analog scale (one-five, with one being never bloated and five being always bloated) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LOA005
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Data is proprietary
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .